MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.lungcan.2022.12.004

Медицинская библиотека · Lung cancer (Amsterdam, Netherlands) · 2022

Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial.

Peters Solange, Letovanec Igor, Mauer Murielle, Dafni Urania, Ejedepang Dunson, Biernat Wojciech, Bubendorf Lukas, Warth Arne, Pokharel Saraswati, Reinmuth Niels, Majem Tarruella Margarita, Casas-Martin Jose, Tsourti Zoi, Marti Nesa, Kammler Roswitha, Danson Sarah, O'Brien Mary, Stahel Rolf A

Рандомизированное исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND

The primary objective of this study is to evaluate the clinical significance of RANK/L expression, in both a retrospective cohort of surgically resected stage I-III NSCLC (Lungscape) and a randomized clinical trial-cohort (SPLENDOUR) of advanced NSCLC treated with chemotherapy alone or in combination with denosumab.

METHODS

RANK-L expression was assessed on tissue microarrays (TMAs) in Lungscape and whole sections in SPLENDOUR, using immunohistochemistry, with H-scores values > 0 indicating positivity. Prevalence of RANK positivity and its association with clinicopathological characteristics, and patient outcome was explored in a subset of the ETOP Lungscape cohort and in SPLENDOUR. Also investigated were the prevalence of RANK overexpression (proportion of positive cancer cells ≥ 50%) in the Lungscape cohort, and RANK-L in the SPLENDOUR trial.

RESULTS

In the Lungscape cohort, RANK expression was assessed at a median follow-up of 46 months (N = 488 patients; 4 centers); 35% were female, 44/49/6% adenocarcinomas (AC)/squamous cell carcinomas (SCC)/other, 48/27/25% with stage I/II/III. Median RFS/TTR/OS were 58/Not reached/74 months. Prevalence of RANK expression was 31% (95%CI:27%-35%); significantly higher in AC: 50% (95%CI:43%-57%) vs SCC: 12% (95%CI:8%-16%) (p < 0.001); more frequent in females (42% vs 25%, p < 0.001) and tumors ≤ 4 cm (35.3% vs 23.3%, p = 0.0065). No association with outcome was found. In the SPLENDOUR trial (463 patients), the prevalence of membranous and cytoplasmic RANK positivity was 34% (95%CI:30%-38%) and 9% (95%CI:7%-12%), respectively, while prevalence for RANK-L was 5% (95%CI:3%-7%) and 36% (95%CI:31%-40%), respectively. Cytoplasmic RANK-L positivity was more common among females (47% vs 31%, p = 0.001) and in non-SCC histology (45% vs 10%, p < 0.0001). At the pre-specified 1% significance level, no prognostic or predictive effect was found.

CONCLUSIONS

Both cohorts indicate that RANK expression is more common in adenocarcinoma/non-squamous NSCLC and in female patients. No prognostic effect is found, and in the clinical trial involving addition of denosumab to chemotherapy no predictive effect is detected.

Для цитирования: Peters Solange, Letovanec Igor, Mauer Murielle, Dafni Urania, Ejedepang Dunson, Biernat Wojciech, Bubendorf Lukas, Warth Arne, Pokharel Saraswati, Reinmuth Niels, Majem Tarruella Margarita, Casas-Martin Jose, Tsourti Zoi, Marti Nesa, Kammler Roswitha, Danson Sarah, O'Brien Mary, Stahel Rolf A. Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial.. Lung cancer (Amsterdam, Netherlands). 2022. DOI: 10.1016/j.lungcan.2022.12.004.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.